Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €58.39 EUR
Change Today +2.39 / 4.27%
Volume 0.0
As of 6:35 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (EII) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - €77.00
52 Week Low
11/27/14 - €28.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (EII)

Related News

No related news articles were found.

eisai co ltd (EII) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (EII) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; Verastem, Inc.; and Halozyme Therapeutics, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,183 Employees
Last Reported Date: 06/19/15
Founded in 1941

eisai co ltd (EII) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥119.0M
Senior Vice President, Chief Executive Office...
Total Annual Compensation: ¥110.0M
Vice President and President of Eisai Global ...
Total Annual Compensation: ¥68.0M
Vice President, President of Eisai Inc and Ch...
Total Annual Compensation: ¥63.0M
Vice President, President of Neuroscience & G...
Total Annual Compensation: ¥97.0M
Compensation as of Fiscal Year 2015.

eisai co ltd (EII) Key Developments

Eisai Co., Ltd. and Halozyme Therapeutics, Inc. Sign Clinical Collaboration Agreement for Breast Cancer Drug

Eisai Co., Ltd. and Halozyme Therapeutics, Inc. signed a clinical collaboration agreement to evaluate Eisai's anticancer agent, eribulin mesylate, in combination with Halozyme's investigational new drug, PEGPH20, in first line HER2-negative advanced breast cancer. Eribulin, a halichondrin class microtubule dynamics inhibitor with a novel mechanism of action, is currently approved for the treatment of advanced breast cancer in approximately 60 countries worldwide. Structurally, eribulin is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Eribulin is believed to work by inhibition of the growth phase of microtubule dynamics which prevents cell division. PEGPH20 is an investigational drug administered intravenously that targets the degradation of hyaluronan, a glycosaminoglycan - or chain of natural sugars throughout the body. Hyaluronan accumulates around cancer cells, increasing tumor interstitial fluid pressure and constricting tumor vasculature, subsequently inhibiting anticancer agents from reaching cancer cells. By degrading hyaluronan, PEGPH20 increases blood flow to the tumor which may allow cancer therapies to be more efficiently delivered to their target. Under the agreement, the companies will jointly conduct and share the costs of a Phase Ib/II clinical study seeking to determine whether or not the combination therapy of eribulin and PEGPH20 can improve the overall response rate in advanced breast cancer patients with high levels of hyaluronan. In hyaluronan-rich triple-negative breast preclinical animal models, the addition of PEGPH20 to eribulin showed a significantly higher tumor growth inhibition including tumor regression when compared to eribulin alone.

Eisai Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Provides Earnings Guidance for the Six Months and Year Ending March 31, 2016

Eisai Co., Ltd. announced consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, the company reported revenue of JPY 139,249 million compared to JPY 132,829 million a year ago. Operating profit was JPY 7,613 million compared to JPY 8,466 million a year ago. Profit before income taxes was JPY 7,438 million compared to JPY 7,729 million a year ago. Profit for the period was JPY 5,520 million compared to JPY 5,730 million a year ago. Profit for the period attributable to owners of the parent was JPY 5,445 million or JPY 19.01 per diluted share compared to JPY 5,678 million or JPY 19.89 per diluted share a year ago. Net cash from operating activities was JPY 21,131 million compared to JPY 7,941 million a year ago. Purchases of property, plant and equipment was JPY 1,468 million compared to JPY 2,009 million a year ago. Purchases of intangible assets JPY 30,136 million compared to JPY 1,220 million a year ago. Return on equity was nil compared to 7.6% a year ago. The company provided earnings guidance for the six months and year ending March 31, 2016. For the six months ending September 30, 2015, the company expects revenue of JPY 277,500 million, operating profit of JPY 10,000 million, profit before income taxes of JPY 8,400 million, profit for the year of JPY 6,000 million, basic earnings per share attributable to owners of the parent of JPY 20.66. For the year ending March 31, 2016, the company expects revenue of JPY 556,500 million, operating profit of JPY 46,000 million, profit before income taxes of JPY 42,800 million, profit for the year of JPY 27,000 million, basic earnings per share attributable to owners of the parent of JPY 93.83.

Eisai Co., Ltd. Provides Dividend Guidance for the Second Quarter and End of Year of Fiscal 2016

Eisai Co., Ltd. provided dividend forecast of ¥70 per share for second quarter of fiscal 2016 and ¥80 per share for the end of year of fiscal 2016, both dividends are same as a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EII:GR €58.39 EUR +2.39

EII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €17.23 EUR +0.19
Nektar Therapeutics $10.87 USD +0.04
Ono Pharmaceutical Co Ltd ¥15,560 JPY +440.00
Shire PLC 5,025 GBp +10.00
Synergy Health PLC 1,625 GBp +35.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EII Industry Range
Price/Earnings 52.2x
Price/Sales 4.0x
Price/Book 3.8x
Price/Cash Flow 54.2x
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at